C12N 2740/11022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/11022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 45 US grants and 25 published applications in this corpus.
Search patents in C12N- Granted patents
- 45
- Published applications
- 25
- Assignees
- 28
- Inventors
- 104
- Latest grant
- 7 May 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 4 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 3 | 0 |
| 1996 | 5 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 1 |
| 2004 | 1 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 1 |
| 2008 | 1 | 0 |
| 2009 | 1 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 1 |
| 2016 | 1 | 2 |
| 2017 | 2 | 2 |
| 2018 | 2 | 0 |
| 2019 | 0 | 2 |
| 2020 | 1 | 2 |
| 2021 | 0 | 1 |
| 2022 | 2 | 0 |
| 2023 | 0 | 4 |
| 2024 | 2 | 2 |
| 2025 | 0 | 3 |
By publication year. Applications have been published since 2001.
Recent patents
- Particle delivery systems7 May 2024US 11,976,277 B2Scribe Therapeutics Inc.
- RNA-based delivery systems with levels of control2 Apr 2024US 11,946,066 B2California Institute of Technology
- RNA-based delivery systems with levels of control27 Sep 2022US 11,453,893 B2California Institute of Technology
- Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity18 Jan 2022US 11,225,673 B2Bavarian Nordic A/S
- Delivery of packaged RNA to mammalian cells21 Jan 2020US 10,538,743 B2The USA, as represented by the Secretary, Dept. of Health and Human Services
- Glycoproteins for pseudotyping retroviral vector particles25 Dec 2025US 2025/0388924 A1Medizinische Hochschule Hannover
- Alpharetrovirus-based particles for delivery of rna into cells30 Oct 2025US 2025/0333759 A1Medizinische Hochschule Hannover
- Compositions, systems, and methods for prime editing29 May 2025US 2025/0171810 A1The Trustees of Columbia University in the City of New York
- Self-Amplifying RNA-Based VLP Vaccines22 Aug 2024US 2024/0277836 A1Chimeron Bio Corporation
- Compositions and methods for tracing cell networks9 May 2024US 2024/0151709 A1The Brigham and Women S Hospital, Inc.
Most cited
By later US patents
- Transgenic non-human mammals531US 4,736,866 APresident and Fellows of Harvard College · 1988
- Composition for introducing nucleic acid complexes into higher eucaryotic cells257US 5,547,932 ABoehringer Ingelheim International GmbH · 1996
- Production of reverse transcriptase91US 4,663,290 AMolecular Genetics, Inc. · 1987
- Biologically active B-chain homodimers87US 4,845,075 AZymoGenetics, Inc. · 1989
- PDGF analogs and methods of use46US 5,128,321 AZymoGenetics, Inc. · 1992